Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (RSPAD Gatot Soebroto)
- Development stage
- Unknown
- Lead developer
- Gatot Soebroto Central Army Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) developed at Rumah Sakit Pusat Angkatan Darat (RSPAD) Gatot Soebroto are a cell-based therapy being evaluated for the treatment of keloids. These multipotent cells possess significant immunomodulatory and anti-fibrotic properties, which they exert primarily through paracrine signaling. By secreting various cytokines, growth factors, and extracellular vesicles, UC-MSCs inhibit the over-proliferation of keloid fibroblasts and suppress the excessive deposition of extracellular matrix components, particularly collagen, by modulating the TGF-beta/Smad signaling pathway. This therapeutic approach aims to reduce the size, height, and symptoms of keloids, offering a potential alternative or adjunct to traditional treatments like corticosteroid injections. The treatment is typically administered via intralesional injection directly into the keloid tissue.
- Other names
- Human umbilical cord mesenchymal stem cellsUC-MSCshUC-MSCs
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (RSPAD Gatot Soebroto).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (RSPAD Gatot Soebroto).